Global Bispecific Antibody Market Surpasses $8.5 Billion in H1 2025, Projected to Exceed $18 Billion Annually

▎Armstrong

In the first half of 2025, the global bispecific antibody market size exceeded 8.5 billion US dollars (sales data for Akeso's bispecific antibodies not disclosed), representing a 40% increase compared to the first half of 2024. Full-year sales are projected to surpass 18 billion US dollars.

Roche remains the leader in the bispecific antibody field, with three bispecific antibodies in the hematology sector, including Hemlibra for hemophilia FIX/FX, and two CD3/CD20 bispecific antibodies. The penetration of Hemlibra among non-inhibitor patients continues to accelerate, while the two CD3/CD20 bispecific antibodies are experiencing rapid growth in DLBCL and FL, respectively.

VEGF/Ang2 Bispecific Antibody Sales Reach $2.64 Billion in the First Half of the Year, Expected to Exceed $5 Billion for the Full Year; Rapid Growth in China After Inclusion in the National Reimbursement Drug List.

Amgen's Two Bispecific Antibodies Are Both TCEs: The CD3/CD19 Bispecific for Hematological Tumors Maintains Rapid Growth, While Expanding Into Autoimmune Indications. The DLL3/CD33 Bispecific for Solid Tumors Achieved Rapid Sales Growth Post-Launch, with First-Half Revenue Reaching $215 Million.

Genmab's CD3/CD20 bispecific antibody Epkinly achieved sales of $211 million in the first half of the year, representing a 74% year-over-year increase.

Johnson & Johnson's EGFR/cMET bispecific antibody achieved $320 million in sales in the first half of the year, while two TCEs for hematologic tumors, the BCMA/CD3 bispecific antibody and GPRC5D/CD3 bispecific antibody, also maintained rapid growth.

Summary

The bispecific antibody drug market size is expected to continue its rapid expansion in the coming years. TCE itself is also tapping into the autoimmune market, which represents another new track with extremely high potential. Akeso’s tumor immunotherapy bispecific antibodies, including PD-1/VEGF, are expected to replace PD-1 as a new cornerstone of immunotherapy, prompting many multinational corporations (MNCs) to invest in this direction. In summary, the bispecific antibody drug market is at the turning point before a second phase of rapid growth, and numerous breakthroughs are anticipated in the coming years.